Targeting S100A9–ALDH1A1–Retinoic Acid Signaling to Suppress Brain Relapse in EGFR-Mutant Lung Cancer

The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib has significantly prolonged progression-free survival (PFS) in patients with EGFR-mutant lung cancer, including those with brain metastases. However, despite striking initial responses, osimertinib-treated patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Biswas, Anup Kumar, Han, Seoyoung, Tai, Yifan, Ma, Wanchao, Coker, Courtney, Quinn, S. Aidan, Shakri, Ahmad Rushdi, Zhong, Timothy James, Scholze, Hanna, Lagos, Galina G., Mela, Angeliki, Manova-Todorova, Katia, de Stanchina, Elisa, Ferrando, Adolfo A., Mendelsohn, Cathy, Canoll, Peter, Yu, Helena A., Paik, Paul K., Saqi, Anjali, Shu, Catherine A., Kris, Mark G., Massague, Joan, Acharyya, Swarnali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983473/
https://www.ncbi.nlm.nih.gov/pubmed/35078784
http://dx.doi.org/10.1158/2159-8290.CD-21-0910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983473/
https://www.ncbi.nlm.nih.gov/pubmed/35078784
http://dx.doi.org/10.1158/2159-8290.CD-21-0910

Ejemplares similares